Alice Johnson Telescope

Diagnosis: Stage IV Non-Small Cell Lung Cancer (Adenocarcinoma) • Location: Cambridge, MA • Created: 2026-07-12 11:30

3 Matched Clinical Trials

Incoming Recruiter Invitation Received Yesterday at 2:30 PM

Dr. Sarah Chen, MD • Dana-Farber Cancer Institute

Lead Clinical Research Coordinator, Center for Thoracic Oncology

NCT05481234

Phase 2 Study of Targeted Combination Therapy in EGFR-Mutated Advanced NSCLC

Site: Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115

Note from Dr. Sarah Chen:

Dear Patient, Our clinical research team at Dana-Farber Cancer Institute has reviewed your de-identified case summary on Eligara and identified your clinical profile as a potential match for our enrolling targeted therapy trial (NCT05481234: Osimertinib + Combination in EGFR-Mutant NSCLC). If you are interested in exploring whether this trial could be an appropriate next step in your treatment plan, please tap 'I am Interested in Connecting' below. We would be delighted to provide comprehensive trial documentation and discuss with you or your treating oncologist. Best regards, Dr. Sarah Chen, MD Lead Study Coordinator, Dana-Farber Cancer Institute

🔒

HIPAA Privacy Protection: The study team at Dana-Farber screened your case under de-identified identifier Candidate #PT-9481. Your name and contact coordinates remain completely hidden until you affirmatively click "I'm Interested in Connecting".

AI Clinical Synthesis & Staging

**Demographics**: 62-year-old female | **Histology**: Non-Small Cell Lung Adenocarcinoma | **Stage**: Stage IV (cT2aN1M1b - solitary stable CNS metastasis post-SRS) | **Genomic Alterations**: EGFR Exon 19 deletion (p.E746_A750del), T790M (-), C797S (-), PD-L1 TPS 15% | **Prior Systemic Therapy**: 1st-generation EGFR TKI (Erlotinib) x 14 months; recent radiological progression in lung | **Performance Status**: ECOG 1 | **Comorbidities**: Mild osteopenia, no significant cardiac or renal disease.

View Original Clinical Notes Entered

Patient is a 62yo female diagnosed in Nov 2024 with Stage IV lung adenocarcinoma, primary right lower lobe with solitary asymptomatic cerebellar lesion treated with SRS in March 2025. Tissue biopsy NGS revealed EGFR Exon 19 deletion (p.E746_A750del). T790M and C797S negative. Started erlotinib 150mg daily, tolerated well with good partial response for 14 months. Recent surveillance chest CT on 8/28/2026 shows enlargement of right lung primary mass (2.1cm to 3.4cm) consistent with progression. Brain MRI shows no new lesions. Seeking clinical trials with next-generation EGFR-targeted agents or combination protocols.

Key Eligibility Checklist

Indication: Non-Small Cell Lung Cancer

Histology: Adenocarcinoma

Stage: Stage IV

ECOG Status: 1

CNS Mets: Stable / Treated (SRS)

Molecular Alterations:

EGFR Exon 19 del T790M negative PD-L1 15%

Top Matched Clinical Trials

Ranked by AI matching score against protocol inclusion and exclusion criteria.

3 Recruiting Studies

Phase 2 NCT05481234 • Dana-Farber Cancer Institute / Alliance Oncology

Phase 2 Study of Targeted Combination Therapy in EGFR-Mutated Advanced NSCLC

A prospective open-label Phase 2 study evaluating third-generation EGFR TKI in combination with bispecific antibody therapy in patients with advanced non-small cell lung cancer harboring sensitizing EGFR mutations following frontline disease progression.

📍 Location: Boston, MA (Dana-Farber Cancer Institute, 4.2 miles away)

★ 96% Match

Save to Cart

Why this trial matches:

✓ Matches EGFR Exon 19 deletion
✓ Eligible with prior 1st-generation TKI progression
✓ Permits treated asymptomatic CNS metastases
✓ Local trial center within 5 miles

Phase 1/2 NCT04988295 • Massachusetts General Hospital Cancer Center

Study of Novel Brain-Penetrant TKI in Patients with EGFR-Mutant NSCLC and CNS Metastases

Evaluating efficacy and safety of a next-generation brain-penetrant kinase inhibitor in metastatic NSCLC patients with documented active or treated intracranial lesions.

📍 Location: Boston, MA (Mass General Cancer Center, 4.8 miles away)

★ 91% Match

Save to Cart

Why this trial matches:

✓ Matches EGFR mutation and Stage IV staging
✓ Directly targets intracranial disease stability
✓ Center in Boston medical area

Phase 3 NCT05129931 • Beth Israel Deaconess Medical Center

Subsequent-Line Bispecific Antibody vs Chemotherapy in Pretreated Non-Small Cell Lung Cancer

Phase 3 randomized multicenter trial comparing dual-specific immunotherapy versus standard pemetrexed chemotherapy in pretreated metastatic lung adenocarcinoma.

📍 Location: Boston, MA (BIDMC, 5.1 miles away)

★ 84% Match

Save to Cart

Why this trial matches:

✓ Eligible for second-line systemic therapy
✓ Acceptable organ metrics and performance status